Bulletin from Annual General Meeting of Diamyd Medical AB
The Annual General Meeting of Diamyd Medical AB (publ) was held on December 1, 2022. Full information and documents regarding the Annual General Meeting's resolutions can be found on the Company's website, https://www.diamyd.com. All resolutions passed by the Annual General Meeting are in accordance with the proposals presented in the notice.
The Company's income statement and balance sheet were adopted, and the Board members and the Chief Executive Officer were discharged from liability for the fiscal year 2021/2022. The Annual General Meeting approved the Board's proposal that no dividend be paid for the fiscal year 2021/2022. Erik Nerpin was re-elected as Chairman of the Board and Anders Essen-Möller, Maria-Teresa Essen-Möller, Torbjörn Bäckström, Mark A. Atkinson and Karin Hehenberger were re-elected to the Board
The Annual General Meeting approved the proposed remuneration to Board members and the Chairman of the Board.
The Annual General Meeting resolved to re-elect the auditing company BDO until the end of the Annual General Meeting 2023. Principal auditor is the authorized public accountant Johan Pharmanson.
The Annual General Meeting resolved to authorize the Board, on one or more occasions prior to the next Annual General Meeting to issue shares and to deviate from the shareholders' preferential rights when so doing. Payment may be made in cash, through a contribution or by offsetting. In a share issue for cash payment and in deviation from the shareholders' preferential rights, the number of shares issued pursuant to the authorization may not exceed 20 percent of the shares in the Company when the share issue occurs.
The Annual General Meeting approved in accordance with the Board’s proposal to implement a new performance-based incentive program for employees within Diamyd Medical (“LTI 2022”), meaning that a total of 30 employees within Diamyd Medical can participate. The program runs over approximately 3 years and the participants in LTI 2022 will be given the opportunity to be granted the right to acquire B shares in Diamyd Medical free of charge at a subscription price corresponding to the share’s quote value within the framework of LTI 2022, or receive a warrant entitling them to subscribe for one share free of charge in Diamyd Medical at a subscription price corresponding to the quote value of the share, “Performance share rights”. In the event of a maximum outcome of Performance share rights, 300 000 B shares can be allocated to participants according to LTI 2022, and a further 46 500 B shares can be used to cover for social security costs as a result of LTI 2022, which constitutes a dilution effect of approximately 0.45 percent of the total number of shares in the Company.
About Diamyd Medical
Diamyd Medical develops precision medicine therapies for Type 1 Diabetes. Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. DIAGNODE-3, a confirmatory Phase III trial is actively recruting patients with recent-onset Type 1 Diabetes in eight European countries. Significant results have previously been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where Diamyd® was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. A manufacturing facility is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the antigen-specific immunotherapy Diamyd®. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen® trial in individuals living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB.
Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.
For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: firstname.lastname@example.org Reg. no.: 556242-3797 Website: https://www.diamyd.com
The information was submitted for publication, through the agency of the contact person set out above, at 17.00 CET on December 1, 2022.